Please login to the form below

Not currently logged in
Email:
Password:

Sagent appoints Michael Fekete to board

Will support growth of injectables firm following initial public offering

Sagent Pharmaceuticals has appointed Michael Fekete as the sixth member of its board of directors.

Fekete is currently director at both pharma firm DFB Pharmaceuticals and Symetis SA, which creates minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.

He is a corporate adviser specialising in capital markets, mergers and acquisitions and general corporate strategy and has experience at Oppenheimer & Co and L F Rothschild & Co.

Illinois, US-based injectable specialist Sagent will benefit from his advice as it looks to expand following its successful initial public offering, which Fekete assisted in an advisory role.

“Mike's experience and skill set will be particularly valuable to us as we continue to drive our growth,” said Jeffrey Yordon, founder, CEO and chairman of the board of Sagent.

“We look forward to his contribution to the board of directors and his involvement with senior management of the company."

16th July 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics